Abstract
Current guidelines for treating GBS do not recommend combining the two available treatments, intravenous immunoglobulins (IVIG) and therapeutic plasma exchange (TPE), in any sequential order due to a lack of evidence of additional benefit. 1,2,3 A reference work on GBS specifically recommends against TPE after IVIG. 4 Nevertheless, combination therapy, mostly IVIG followed by TPE for difficult-to-treat GBS, is still reported. 5,6,7 This practice has also been directly observed by and reported in personal communications to the author. The question therefore arises: why do clinicians follow non-recommended procedures when confronted with less-than-optimal response to IVIG? And is there any rationale to support it? Here we try to find an answer to these questions in light of the current observational evidence, immunopathogenesis of the disease, and the mechanisms of action of the two therapeutic treatments.Guillain-Barré Syndrome (GBS) is an acute autoimmune polyradiculoneuropathy which often follows bacterial or viral infections. 4 Molecular mimicry is the proven mechanism mediating autoimmunity after C. jejuni infection in the axonal variants of GBS (acute motor axonal neuropathy, AMAN, and acute motor and sensory axonal neuropathy, AMSAN) and is a consequence of the structural similarity between the bacterial lipooligosaccharide and the GM1 and GD1a gangliosides present in the nodes of Ranvier and paranodal areas of peripheral nerves. 8,9 The pathogenesis of the demyelinating variant (acute inflammatory demyelinating polyradiculoneuropathy, AIDP) of GBS is less understood. Although some cases might be associated with anti-galactocerebroside autoantibodies, autoimmunity in AIDP appears to be driven by T-cell activation and cytokines like IFN-γ, TNF-α, and IL-6. 10,11,12 Indeed, most patients suffering from GBS test negative for anti-ganglioside antibodies, especially in the clinical-electrophysiological AIDP variant, suggesting that other immune-mediated mechanisms are involved in GBS and that such alternative mechanisms are prevalent in the demyelinating variant. 13 Recently, autoreactive CD4+ cytotoxic T helper 1 and CD8+ T cells targeting antigens of the peripheral nerve myelin sheath were detected in patients with AIDP. 14 Nevertheless, anti-GM1 antibodies can also be found in AIDP. 15 Moreover, both axonal and demyelinating subtypes of GBS can be mediated by complement-fixing anti-GM1 antibodies. 16 Binding of the C1q complement component to antibodies recognizing peripheral nerves activates the classical complement pathway on the nerve surface, thus driving neuroinflammation and nerve damage. 17,18 Evidence also suggests that classical complement activation underlies nerve injury in GBS regardless of axonal or demyelinating pathophysiology. 17,18 The axonal vs demyelination dichotomy in GBS diagnosis is supported by the electrophysiological study of nerve conduction, classically capable of distinguishing signs of axonal degeneration, like decreased distal compound muscle action potential (CMAP) amplitudes, from signs of damage to the myelin sheet, such as increased CMAP latency and temporal dispersion. Nevertheless, electrophysiology too might sometimes fail to be conclusive especially in the early phase of disease. Indeed, both demyelinating and axonal forms may manifest with nerve conduction blocks as shown by reduced ratio of proximal vs distal CMAPs. These blocks are usually longer lasting in AIDP whereas they tend to resolve quickly in anti-GM1 associated AMAN/AMSAN. The rapidly resolving conduction blocks in axonal GBS forma have therefore been named reversible conduction failure (RCF) and are considered a sign of nodal dysfunction.The previous paragraph briefly described the variability in the molecular mechanisms underlying a diagnosis of GBS. Two patients with the same diagnosis of GBS might be victims of either abnormal T-cell activation targeting myelin, predominant molecular-mimicry-elicited humoral autoimmunity damaging the nodal-paranodal portions of the nerve, or both. Nevertheless, neither the clinical-electrophysiological aspects nor the immunopathogenetic mechanisms of the disease are of therapeutic relevance in clinical practice. 1 Currently, GBS therapy consists of intravenous immunoglobulins (IVIG) and therapeutic plasma exchange (TPE). Historically, TPE was the first treatment adopted. 19 Subsequent RCTs comparing IVIG to TPE did not show evidence for superiority of one therapy over the other, and there are currently no identified subgroups of patients showing increased benefit from either TPE, IVIG, or TPE followed by IVIG.1 The European guidelines and the latest GBS reference work from The Lancet both argue that TPE after IVIG washes out the previous treatment, which is considered expensive and irrational 1,4 Indeed, although direct evidence on IVIG removal by TPE is actually limited, immunoglobulins are likely to be significantly removed by plasma exchange. 20 Pharmacodynamics of IVIG IVIG comprises about 90% IgG and exerts immunomodulatory functions through a variety of mechanisms. 21 It can bind and neutralize circulating autoantibodies, the anaphylatoxins C3a and C5a, and other complement proteins. At high doses, IgG in IVIG saturates activating Fcγ receptors (FcγRs) on immune cells, thereby blocking their activation and reducing immune complex-driven inflammation and autoimmunity. IVIG also suppresses the activation of monocytes and macrophages and interferes with the maturation and differentiation of dendritic cells. In addition, it promotes the release of anti-inflammatory cytokines by innate immune cells and exerts cytotoxic effects on neutrophils and eosinophils. IVIG can trigger apoptosis in dendritic cells as well as effector Th1 and Th17 cells, while enhancing immunosuppressive pathways through expansion of regulatory T cells. Furthermore, it inhibits B-lymphocyte proliferation, thereby modulating antibody production....

This publication has 40 references indexed in Scilit: